BioSpace News Archive

Syros Pharmaceuticals today announced a peer-reviewed publication of results from its completed biomarker-directed Phase 2 trial of tamibarotene in combination with azacitidine in newly diagnosed patients with acute myeloid leukemia (AML) who are not eligible for standard intensive chemotherapy.

Black Diamond Therapeutics, Inc. today announced the formation of Launchpad Therapeutics, Inc.

VYNE Therapeutics Inc. announced that management is scheduled to participate at the LifeSci Partners 12th Annual Corporate Access Event being held during the week of the J.P. Morgan Healthcare Conference, in San Francisco, CA and will be available for one-on-one meetings.

Meridian Bioscience, Inc. announced that it has entered into a side letter with the buyer, setting the closing date of Meridian’s pending merger for January 31, 2023.

Serenus.AI will present its work for the development of an AI-based Personalized CDSS for the Treatment of Chronic Lymphocytic Leukemia (CLL), at the 2022 annual ASH meeting.

Juno Diagnostics today announced that JunoDx’s Founder and Chief Executive Officer, Dirk van den Boom, will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 2:00 PM.

Akron Bio today announced the appointment of Christopher Murphy as Chief Executive Officer.

Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (rtCGM), announced today its partnership with Green Shield and The Health Depot digital pharmacy to provide Green Shield plan members with convenient access to the Dexcom G6 rtCGM System combined with virtual diabetes coaching support.

ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants.

Blue Water Vaccines Inc. today announced its first analyst coverage since going public in February 2022 with the initial recommendations as “buy” from both Maxim Group LLC (“Maxim”) and H.C. Wainwright & Co. (“H.C. Wainwright”) at price targets of $4 and $7, respectively.